In April this year, Bavarian Nordic commenced a Phase III VANIR trial of the RSV vaccine. Credit: Towfiqu barbhuiya on Unsplash.

The Chinese Center for Drug Evaluation (CDE) has granted clearance for Nuance Pharma’s Investigational New Drug (IND) application for a Phase III clinical trial of an MVA-BN RSV vaccine for use in adults with respiratory syncytial virus (RSV) infection in the country.

In April this year, Bavarian Nordic commenced an international, double-blind, randomised, Phase III VANIR trial of this vaccine.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial has been designed to enrol 20,000 adults aged 60 years and above by the end of this year. 

It is being carried out at nearly 115 sites in Germany and the US, with topline data expected mid-next year.

The MVA-BN RSV vaccine is being developed for the prevention of RSV infection in older adults. 

See Also:

It comprises five separate RSV antigens to induce a wide-ranging immune response against both RSV subtypes (A and B).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based on the MVA-BN platform technology of Bavarian Nordic, the vaccine imitates the immune response seen after a natural response to an RSV infection. 

Nuance Pharma and Bavarian Nordic signed an agreement last year for exclusive rights for the development and marketing of the vaccine in the Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea, and Southeast Asia.

Nuance Pharma CEO and co-founder Mark Lotter said: “This is a significant milestone for Nuance Pharma, and we are confident that we will achieve solid and inspiring progress for the development of [the] MVA-BN RSV vaccine in China. 

“The MVA-BN RSV vaccine holds the potential to become the first to market adult RSV vaccine in China. 

“MVA-BN RSV represents another example of Nuance’s capability to bring differentiated solutions to address unmet medical needs in the respiratory space in China and the Asian markets.”